These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9267781)

  • 41. Staging of prostate cancer: a review with reference for further refinement.
    Pospihalj B
    Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):69-74. PubMed ID: 26072637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods.
    Huch Böni RA; Boner JA; Debatin JF; Trinkler F; Knönagel H; Von Hochstetter A; Helfenstein U; Krestin GP
    Clin Radiol; 1995 Sep; 50(9):593-600. PubMed ID: 7554732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics of prostate cancer found with early detection regimens.
    Brendler CB
    Urology; 1995 Sep; 46(3 Suppl A):71-6. PubMed ID: 7544517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors.
    Villers A; McNeal JE; Freiha FS; Stamey TA
    Cancer; 1992 Nov; 70(9):2313-8. PubMed ID: 1382830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
    Cooke EW; Shrieve DC; Tward JD
    Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy of transrectal ultrasonography in staging prostate cancer].
    Soh S; Egawa S
    Nihon Rinsho; 1998 Aug; 56(8):2036-41. PubMed ID: 9750503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
    Oesterling JE; Suman VJ; Zincke H; Bostwick DG
    Urol Clin North Am; 1993 Nov; 20(4):687-93. PubMed ID: 7505977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy of transrectal ultrasound and prostate cancer.
    Mandell MJ; Hopper KD; Jarowenko MV; Rohner TJ; Belis JA; Stryker JA; Meilstrup JW; Thieme GA
    Crit Rev Diagn Imaging; 1991; 32(4):273-300. PubMed ID: 1958294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
    Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT
    J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
    Epstein JI
    J Urol; 2011 Sep; 186(3):790-7. PubMed ID: 21788055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two year experience with transrectal prostate ultrasound.
    Badalament RA; York JP; Drago JR
    In Vivo; 1990; 4(5):325-6. PubMed ID: 1723013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.
    Bostwick DG; Montironi R
    Virchows Arch; 1997 Jan; 430(1):1-16. PubMed ID: 9037309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?
    Ohori M; Kattan MW; Utsunomiya T; Suyama K; Scardino PT; Wheeler TM
    J Urol; 2003 Mar; 169(3):964-8. PubMed ID: 12576823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary staging of prostate cancer.
    Jager GJ; Barentz JO; Ruijter ET; de la Rosette JJ; Oosterhof GO
    Eur Radiol; 1996; 6(2):134-9. PubMed ID: 8797969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current aspects of the diagnosis and treatment of prostatic cancer].
    Petrov SB; Veliev EI; Shpilenia ES; Goriachev IA
    Vestn Khir Im I I Grek; 1998; 157(5):44-8. PubMed ID: 9915057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical assessment of prostate cancer staging.
    Graham SD
    Cancer; 1992 Jul; 70(1 Suppl):269-74. PubMed ID: 1376195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.